Microbiome Derived Live Biotherapeutic Products Market

According to Stratistics MRC, the Global Microbiome-Derived Live Biotherapeutic Products Market is accounted for $0.4 billion in 2026 and is expected to reach $2.5 billion by 2034 growing at a CAGR of 25.8% during the forecast period. The Microbiome-Derived Live Biotherapeutic Products Market encompasses pharmaceutical preparations containing living microorganisms designed to prevent or treat diseases by restoring microbial balance and influencing host biological functions. Increasing prevalence of gastrointestinal disorders, growing understanding of microbiome-associated diseases, and advancements in microbial therapeutics are supporting market development. Innovations in defined microbial consortia, bacterial strain selection, and pharmaceutical manufacturing improve treatment capabilities. Expanding clinical research and regulatory approvals create additional opportunities.

Market Dynamics:

Driver:

Increasing prevalence of gastrointestinal disorders and advancements in microbiome therapeutics

Increasing prevalence of gastrointestinal disorders and advancements in microbiome therapeutics are driving market growth. Rising incidence of recurrent Clostridioides difficile infection and growing awareness of intestinal microbial imbalance encourage development of targeted microbial treatments. Live biotherapeutic products aim to restore beneficial microbial communities and improve resistance against pathogenic organisms. Regulatory approvals of microbiota-based therapies have strengthened clinical interest in this therapeutic category. Advances in microbial sequencing, strain identification, and formulation technologies further support product development and adoption.

Restraint:

Complex manufacturing requirements and challenges in microbial product standardization

Complex manufacturing requirements and challenges in microbial product standardization restrain market growth. Live biotherapeutic products require stringent controls over microbial identity, viability, potency, purity, and contamination risks. Manufacturing defined microbial communities involves specialized fermentation, anaerobic processing, and stability testing. Differences in microbial composition and patient microbiome characteristics may influence treatment outcomes. Limited long-term clinical evidence for several emerging indications creates additional uncertainty. High production costs, regulatory complexity, and specialized distribution requirements further restrict commercialization.

Opportunity:

Expansion of microbiome-based treatments for inflammatory and immune-mediated diseases

Expansion of microbiome-based treatments for inflammatory and immune-mediated diseases presents significant growth opportunities. Biotechnology companies are investigating defined bacterial consortia and engineered microorganisms for inflammatory bowel disease, oncology supportive care, metabolic disorders, and immune-related conditions. Growing understanding of microbiome interactions with host immunity encourages therapeutic innovation. Advances in microbial genomics, precision fermentation, and targeted delivery technologies support pipeline diversification. Strategic collaborations among pharmaceutical companies, biotechnology developers, and academic institutions are expected to accelerate clinical research and commercialization.

Threat:

Safety concerns and competition from conventional pharmaceutical treatments

Safety concerns and competition from conventional pharmaceutical treatments pose significant challenges to market development. Live biotherapeutic products must demonstrate consistent microbial composition, acceptable safety profiles, and reliable clinical effectiveness. Potential contamination, unintended microbial transmission, and infection risks require careful monitoring, particularly among immunocompromised patients. Antibiotics, biologics, and other established treatments provide competing therapeutic options. Regulatory scrutiny, reimbursement uncertainty, and variability in patient microbiome responses may further influence clinical adoption and commercialization strategies.

Covid-19 Impact:

The COVID-19 pandemic disrupted microbiome research through delayed clinical trials, restricted healthcare access, and interruptions in specialized microbial manufacturing supply chains. Gastroenterology services experienced changes in patient consultations and treatment schedules, affecting clinical enrollment and product development. However, increasing scientific interest in microbiome interactions with immune function encouraged additional research into microbial therapeutics. Biotechnology companies strengthened manufacturing resilience and adopted modified clinical protocols. Post-pandemic recovery in gastrointestinal care and expanding investment in microbiome science continue to support market development.

The donor-derived microbiota products segment is expected to be the largest during the forecast period

The donor-derived microbiota products segment is expected to account for the largest market share during the forecast period due to established clinical applications in preventing recurrent Clostridioides difficile infection. These products contain screened donor-derived microbial communities designed to restore intestinal microbiome diversity following antibiotic treatment. Regulatory approvals of microbiota-based therapies have supported clinical adoption and commercial development. Growing awareness of recurrent infection management encourages treatment demand. Advances in donor screening, microbial processing, and pharmaceutical quality controls further strengthen segment prospects.

The defined microbial consortia segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the defined microbial consortia segment is predicted to witness the highest growth rate due to increasing development of standardized microbial formulations containing selected bacterial strains. These products aim to deliver reproducible microbial compositions with specific therapeutic functions. Growing investigation of inflammatory bowel disease, metabolic disorders, and immune-mediated conditions encourages pipeline expansion. Advances in microbial strain selection, controlled fermentation, and formulation stability support innovation. Expanding clinical research and pharmaceutical partnerships could accelerate commercialization.

Region with largest share:

During the forecast period, North America is expected to hold the largest market share due to advanced biotechnology infrastructure, established pharmaceutical research capabilities, and growing adoption of microbiota-based treatments. The United States and Canada support live biotherapeutic development through specialized gastroenterology centers, clinical trial networks, and microbial manufacturing facilities. Regulatory progress in recurrent Clostridioides difficile infection treatment encourages commercial activity. Increasing investment in microbiome research and expanding biotechnology partnerships further strengthen North America's market position.

Region with highest CAGR:

Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding healthcare infrastructure, increasing gastrointestinal disease awareness, and growing investment in microbiome research. China, Japan, South Korea, India, and Australia are advancing microbial therapeutics development and biotechnology manufacturing capabilities. Government-supported life sciences initiatives and expanding clinical research networks encourage innovation. Improvements in microbial sequencing, pharmaceutical production, and access to specialized gastroenterology services are expected to accelerate regional market growth.

Key players in the market

Some of the key players in the Microbiome-Derived Live Biotherapeutic Products Market include Ferring Pharmaceuticals, Nestlé Health Science, Seres Therapeutics, Inc., Vedanta Biosciences, Inc., MaaT Pharma, EnteroBiotix Limited, Microbiotica Limited, BiomeBank Pty Ltd., MRM Health NV, Siolta Therapeutics, Inc., Azitra, Inc., AOBiome Therapeutics, Inc., Infant Bacterial Therapeutics AB, Osel, Inc., Servatus Biopharmaceuticals Pty Ltd., Scioto Biosciences, Inc., Prokarium Ltd., and Biomica Ltd.

Key Developments:

In October 2026, MaaT Pharma announced that feedback from the U.S. Food and Drug Administration following a pre-Investigational New Drug meeting supported continued development of MaaT034 for solid tumors. The discussions addressed chemistry, manufacturing, controls, and nonclinical requirements, supporting the company's plans to advance its microbiome-based immunotherapy platform toward clinical evaluation.

In October 2026, Seres Therapeutics, Inc. announced plans to present preclinical findings for SER-428 at IDWeek 2026. The investigational live biotherapeutic uses an oral liquid formulation designed for critically ill patients, including those receiving nutrition through feeding tubes. Preclinical findings indicated reductions in gastrointestinal colonization by clinically relevant pathogens, supporting further investigation into bloodstream infection prevention.

In September 2026, Ferring Pharmaceuticals entered into an agreement granting RedHill Biopharma exclusive global commercialization rights to REBYOTA, an FDA-approved microbiota-based therapy for preventing recurrent Clostridioides difficile infection. The agreement included a $12.0 million upfront payment, potential milestones, and royalties, while Ferring retained manufacturing and supply responsibilities.

Product Types Covered:
• Single-Strain Live Biotherapeutic Products
• Defined Microbial Consortia
• Donor-Derived Microbiota Products
• Engineered Microbial Therapeutics
• Other Product Types

Microbial Compositions Covered:
• Bacterial-Based Products
• Yeast & Fungal-Based Products
• Other Microbial Compositions

Routes of Administration Covered:
• Oral
• Rectal
• Topical
• Other Routes of Administration

Applications Covered:
• Recurrent Clostridioides difficile Infection
• Inflammatory Bowel Disease
• Oncology Supportive Care & Immunotherapy
• Metabolic Disorders
• Allergic & Immune-Mediated Disorders
• Other Applications

End Users Covered:
• Hospitals & Specialty Clinics
• Gastroenterology Centers
• Academic Medical Centers
• Other End Users

Regions Covered:
• North America
o United States
o Canada
o Mexico
• Europe
o United Kingdom
o Germany
o France
o Italy
o Spain
o Netherlands
o Belgium
o Sweden
o Switzerland
o Poland
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Australia
o Indonesia
o Thailand
o Malaysia
o Singapore
o Vietnam
o Rest of Asia Pacific
• South America
o Brazil
o Argentina
o Colombia
o Chile
o Peru
o Rest of South America
• Rest of the World (RoW)
o Middle East
 Saudi Arabia
 United Arab Emirates
 Qatar
 Israel
 Rest of Middle East
o Africa
 South Africa
 Egypt
 Morocco
 Rest of Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances